Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROVARIX Second Dose in Healthy Children
NCT07475000Phase 3Recruiting
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Modality
- Prophylactic Vaccines, DNA Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, open-label trial of varicella virus vaccine live in varicella (VZV) (5 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Geometric Mean Concentration of Varicella-Zoster Virus Antibodies at 42 days and Geometric Mean Fold Rise of Varicella-Zoster Virus Antibodies at 42 days. Started Jan 2026; status: recruiting.
02
Drugs
varicella virus vaccine live
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT07475000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07475000.